Product Images Syeda

This text appears to be a description of a medication package. The medication is called "Drospirenone and Ethinyl Estradiol Tablets, USP" and contains three individual units, each containing one blister pack of 28 tablets, with 21 yellow tablets containing 3mg drospirenone and 0.03mg ethinyl estradiol, followed by 7 white inert tablets. The usual dosage is one tablet daily for 28 consecutive days per menstrual cycle. The medication is manufactured by Laboratorios Ledn Farma S.A., Spain and distributed by Xiromed, LLC in Florham Park NJ. There is also some illegible text that might be a code or reference number.*

Drospirenone Ethinyl estradiol is a combination medication used as a birth control pill to prevent pregnancy. Drospirenone is a progestin and ethinyl estradiol is an estrogen. This medication works by preventing ovulation, thickening the cervical mucus to prevent sperm from reaching the egg, and changing the lining of the uterus to prevent a fertilized egg from implanting. It may also be used to help treat acne in women.*

This text presents a figure showing the VTE (venous thromboembolism) risk associated with the use of Drospirenone and Ethinyl Estradiol relative to other LNG-containing COCs. It includes hazard ratios, rate ratios, and odds ratios obtained from various studies, such as Ingenix, EURAS, LASS, FDA-funded study, Danish study, Danish re-analysis, MEGA study, German case-control, PharMetrics, and GPRD study. The studies include different types of studies such as prospective cohort studies, retrospective cohort studies, and case-control studies. The figure also indicates that the studies considered non-fatal idiopathic cases only.*

This is a figure labeled as Figure 2 that shows the likelihood of developing a VTE (venous thromboembolism) among non-pregnant COC (combined oral contraceptives) users, non-pregnant non-COC users, pregnant women (actual duration) and postpartum women (12 weeks only). The likelihood is represented as the number of women with a blood clot out of 10,000 Women Years (WY), with the ranges varying from 309 to 5020 depending on the group. The rate for pregnancy is assumed to be 7 to 27 per 10,000 WY.*

This text provides information about different methods of birth control and their effectiveness in preventing pregnancies. The text indicates that there are varying rates of pregnancies among women using different contraception methods, ranging from fewer than 1 pregnancy per 100 women per year with certain methods such as implants, injections, intrauterine devices, and sterilization, to 10-20 pregnancies per 100 women per year with other methods such as birth control pills, skin patch, and vaginal ring with hormones. The text also suggests non-hormonal methods such as spermicide and withdrawal, and the option of not using any form of birth control. Overall, the text provides a helpful overview of different options for contraceptive use.*

This text provides information on the likelihood of developing a serious blood clot for non-pregnant women, non-COC users, COC-users, and pregnant/postpartum women. The number of women with a blood clot out of 10,000 Women Years (WY) is shown in a chart. The pregnancy data is based on the actual duration of pregnancy in reference studies and the rate of blood clots is between 7 to 27 per 10,000 WY.*